Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press.

  title={Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press.},
  author={Theodore E. Warkentin and Menaka Pai},
  journal={Thrombosis research},
Epidemiology of VITT
  • M. Pai
  • Medicine
    Seminars in Hematology
  • 2022
VITT is a rare event, but its considerable morbidity and mortality merit ongoing pharmacovigilance, and accurate case ascertainment, based on accurate ascertainment of cases and accurate estimates of the size of the vaccinated population.


Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
Variable patterns of serum-induced platelet activation were observed in response to heparin and platelet factor 4 (PF4), indicating the heterogeneity of the manifestations of VITT in serum.
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome
This review, using data from both peer-reviewed and non-peer-reviewed studies, aimed to provide updated information about the critical issue of COVID-19 vaccine-related TTS, and recommends non-heparin anticoagulants and intravenous immunoglobulins for the treatment of TTS.
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
The high mortality associated with VITT was highest among patients with a low platelet count and intracranial hemorrhage, and identification of prognostic markers may help guide effective management.
Laboratory testing for suspected COVID‐19 vaccine–induced (immune) thrombotic thrombocytopenia
  • E. Favaloro
  • Medicine, Biology
    International journal of laboratory hematology
  • 2021
The laboratory test processes, as utilised to assess suspected VITT, are reviewed, and there are notable similarities and divergences in testing approaches, potentially leading to identification of slightly disparate patient cohorts.
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
It is recommended that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms.
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Findings in five patients who presented with venous thrombosis andThrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19) suggest that they represent a rare vaccine-related variant of spontaneous heparin-induced thromBocytopensia.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia.
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Patient and provider education about the risk for TTS with the Janssen COVID-19 vaccine, especially among women aged <50 years, as well as the availability of alternative CO VID-19 vaccines, is required to guide vaccine decision-making and ensure early recognition and clinical management of TTS.